SLC5A2 and dementia: In time-to-event analyses of dementia-related mortality, treatment with SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors was associated with significantly reduced mortality risk.<h4>Conclusion</h4>Ethnic differences in dementia incidence were attenuated after adjustment for demographic and clinical factors.